Pemetrexed and cisplatin in patients with advanced gastric cancer: A Korean cancer study group multicenter phase II study

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 2, 2008, Pages 263-270

  Kim, Yeul Hong ^a   Chung, Hyun Cheol ^b   Kang, Won Ki ^c   Park, Sook Ryun ^d   Kim, Chul Soo ^e   Kim, Tae Yue ^f   Shin, Sang Won ^a   Park, Byung Joo ^f   Cha, Soo Jin ^g   Bang, Yung Jue ^f  

^a Korea University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Samsung Medical Center   (South Korea)

^d National Cancer Center   (South Korea)

^e Inha University Hospital   (South Korea)

^f Seoul National University Hospital   (South Korea)

^g Lilly Korea   (South Korea)

Author keywords

Advanced gastric cancer; Chemotherapy; Cisplatin; Pemetrexed; Phase II trial

Indexed keywords

CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPONATREMIA; KOREA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; GLUTAMATES; GUANINE; HUMANS; INFUSIONS, INTRAVENOUS; KOREA; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; STOMACH NEOPLASMS;

EID: 43949126887     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0600-y     Document Type: Article

References (33)

1. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137-2150
2. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
3. Parkin DM, Pisani P, Ferlay J (1999) Estimates of the worldwide incidence of twenty-five major cancers in 1990. Int J Cancer 80:827-841
4. Pisani P, Parkin DM, Bray FI, Ferlay J (1999) Estimates of the worldwide mortality from twenty-five major cancers in 1990. Int J Cancer 83:18-29
5. Bae JM, Won YJ, Jung KW, Park J-G (2002) Annual report of the Korea Central cancer Registry program 2000: based on registered data from 131 hospitals. Cancer Res Treat 34:77-83
6. Swan R, Miner TJ (2006) Current role of surgical therapy in gastric cancer. World J Gastroenterol 12:372-379
7. Wils JA, Klein HO, Wagener DJ et al (1991) Sequential high-dose methotrexate and fluorouracil combined with doxorubicin-a step ahead in the treatment of advanced gastric cancer: a trial of the European organization for research and treatment of cancer gastrointestinal tract cooperative group. J Clin Oncol 9:827-831
8. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E et al (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European organization for research and treatment of cancer gastrointestinal tract cancer cooperative group. J Clin Oncol 18:2648-2657
9. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK et al (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15(1):261-267
10. Kim NK, Kim NK, Park YS, Heo DS, Suh C, Kim SY et al (1993) A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71(12):3813-3818
11. Kohne CH, Wils JA, Wilke HJ (2000) Developments in the treatment of gastric cancer in Europe. Oncology (Williston Park) 14:22-25
12. Fuchs CS (1997) Chemotherapy for advanced gastric cancer: where do we stand? J Clin Oncol 15:3299-3300
13. Shih C, Habeck LL, Mendelsohn LG et al (1998) Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 38:135-152
14. Rinaldi DA, Kuhn JG, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG et al (1999) A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 44:372-380
15. Hanauske AR, Chen V, Paoletti P, Niyikiza C (2001) Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 6:363-373
16. Bajetta E, Celio L, Buzzoni R, Ferrari L, Marchiano A, Martinetti A et al (2003) Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann Oncol 14:1543-1548
17. Kim JH, Lee KW, Jung Y, Kim TY, Ham HS, Jong HS et al (2005) Cytotoxic effects of pemetrexed in gastric cancer cells. Cancer Sci 96:365-371
18. Teicher BA, Alvarez E, Liu P, Lu K, Menon K, Dempsey J et al (1999) MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma. Semin Oncol 26:55-62
19. Teicher BA, Chen V, Shih C, Menon K, Forier PA, Phares VG et al (2000) Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res 6:1016-1023
20. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636-2644
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
22. Ajani JA (2005) Evolving chemotherapy for advanced gastric cancer. Oncologist 10(Suppl 3):49-58
23. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE et al (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903-2909
24. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenia M, Boni C et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991-4997
25. Bang YJ, Kang WK, Kang YK, Kim HC, Jacques C, Zuber E et al (2002) Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol 32:248-254
26. Kim YH, Sohn SK, Song HS, Kwon KY, Do YR, Lee KH et al (2007) Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol (Epub ahead of print)
27. Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST et al (2002) Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 13:1893-1898
28. Baek JH, Kim JG, Sohn SK, Kim DH, Lee KB, Song HS et al (2005) Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study. Korean Med Sci 20:966-970
29. Kang Y, Kang KW, Shin DB et al (2006) Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results. J Clin Oncol 24(suppl 20):18s abstr LBA4018
30. Cunningham D, Rao S, Starling N et al (2006) Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: the REAL 2 trial. J Clin Oncol 24(Suppl 20):18s abstr LBA4017
31. Calvert H (2002) Folate status and the safety profile of antifolates. Semin Oncol 29:3-7
32. Niyikiza C, Hanauske AR, Rusthoven JJ, Calvert AH, Allen R, Paoletti P et al (2002) Pemetrexed safety and dosing strategy. Semin Oncol 29:24-29
33. Hammond LA, Forero L, Beeram M, Forouzesh B, De Bono J, Tolcher A, et al (2003) Phase I study of pemetrexed (LY231514) with vitamin supplementation in patients with locally advanced or metastatic cancer. Proc Am Soc Clin Oncol 22:133 (abstr 532)